Basiliximab

Authors: Onrust S.V.; Wiseman L.R.

Source: Drugs, Volume 57, Number 2, February 1999 , pp. 207-213(7)

Buy & download fulltext article:

Price: $68.55 plus tax (Refund Policy)

Abstract:

utrif The chimaeric monoclonal antibody basiliximab specifically binds the alpha subunit of the interleukin-2 (IL-2) receptor on activated T lymphocytes. Through competitive antagonism of IL-2, basiliximab supplements standard immunosuppressive therapy after renal transplantation.

utrif 24 hours after a single intravenous dose of basiliximab 2.5 to 25mg, 90% of available IL-2 receptors on T lymphocytes were complexed with the drug. This level of basiliximab binding was maintained for 4 to 6 weeks when renal transplant patients received basiliximab 20mg 2 hours before and then 4 days after transplantation surgery.

utrif In 2 large, well-designed trials, the percentage of patients with biopsy-confirmed acute rejection episodes after renal transplantation was significantly lower with basiliximab 20mg (administered 2 hours before and then 4 days after transplantation surgery; 30 or 33%, respectively) than placebo (44 or 46%) at 6 months after surgery.

utrif Basiliximab was well tolerated during clinical trials. The incidence of infections (including active cytomegalovirus infection) and post-transplant lymphoproliferative disorders was similar with basiliximab and placebo. Cytokine release syndrome was not observed in patients who received basiliximab.

Keywords: Reviews-on-treatment; Basiliximab, general; Renal-transplant-rejection, prevention; New-drug-profiles; Basiliximab, pharmacokinetics; Basiliximab, pharmacodynamics; Basiliximab, adverse-reactions; Immunosuppressants, therapeutic-use; Basiliximab, therapeutic-use; Clinical-pharmacokinetics; Liver-transplant-rejection